This article was originally published in The Tan Sheet
U.S. Consumer Health sales of $399 mil. declined 2% in the second quarter due to competition from private label ranitidine (Zantac 75), the company reports July 24. The figures, which combine Pfizer and Warner-Lambert's consumer health divisions, are the first reported since Pfizer acquired W-L for roughly $90 bil. (1"The Tan Sheet" Feb. 14, p. 5). Six-month U.S. sales of $821 mil. also declined 1.8%. However, Pfizer notes its oral care business performed well. IRI data for the 52 weeks ending June 18 show Listerine sales totaled $301.4 mil. (up 7.4%), while Zantac 75 sales were down 17.1% to $141 mil. Consolidated sales for the quarter totaled $7.04 bil., up 8%
You may also be interested in...
The combination of Warner-Lambert and Pfizer will create a firm with consumer healthcare sales of over $3.5 bil., based on 1999 results, with W-L contributing roughly $3 bil. of the total.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning